Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NANot yet recruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

October 1, 2026

Study Completion Date

April 1, 2029

Conditions
Type 1 Diabetes (T1D)Type 2 DiabetesDiabetes, AutoimmuneDiabetes MellitusDiabetes Mellitus Type 2Diabetes Mellitus, Type IDiabetes, Type IIDiabetesDiabetes Mellitus, Insulin-DependentDiabetes Mellitus Type IIDiabetes Type 2 on Insulin
Interventions
DEVICE

Bionic Pancreas

The intervention group will use the iLet Bionic Pancreas (BP) for 13-weeks. They will be trained on the iLet BP system and its components by a Certified iLet Trainer. They will also be trained on how to use the study continuous glucose monitor (CGM) system, blood glucose meter, and ketone meter. Participants will have four mid-period follow up phone calls to review medications, ongoing eligibility, and solicit any occurrences of adverse events and device issues. At the end of 13-weeks, they will complete final visit tasks and will be transitioned back to their pre-study insulin delivery method with guidance provided by a study investigator.

OTHER

Routine Care

Participants will continue with their current diabetes treatment. Participants will be trained on the use of the study blood glucose meter. They will have four mid-period follow up phone calls to review medications, ongoing eligibility, and solicit any occurrences of adverse events. At the end of 13-weeks, they will complete final visit tasks and will be asked if they would like to participate in the observational extension phase where they will use the iLet Bionic Pancreas for 13 weeks.

Trial Locations (2)

80045

University of Colorado Anschutz Medical Campus, Aurora

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Beta Bionics, Inc.

INDUSTRY

collaborator

Ann & Robert H Lurie Children's Hospital of Chicago

OTHER

lead

University of Colorado, Denver

OTHER